Mubritinib (TAK-165) 是一种有效且选择性的 EGFR2/HER2 抑制剂,IC50 值为 6 nM。 PACMA 31 是一种不可逆的口服蛋白质二硫异构酶 (PDI) 抑制剂,IC50 为 10 μM。 Tavapadon (PF-06649751) 是一种口服活性、高选择性的多巴胺 D1/D5 受体部分激动剂。Tavapadon 有效促进运动和减少残疾,显示出治疗帕金森病的潜力。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | HER2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Poziotinib |
++++
HER2, IC50: 5.3 nM |
98% | |||||||||||||||||
Tyrphostin AG 879 |
+
HER2-Neu, IC50: 1.0 μM |
95% | |||||||||||||||||
TAK-285 |
+
HER2, IC50: 17 nM |
99%+ | |||||||||||||||||
ARRY-380 analog | ✔ | 98% | |||||||||||||||||
Canertinib |
+++
ErbB2, IC50: 9.0 nM |
EGFR | 99%+ | ||||||||||||||||
(E/Z)-CP-724714 |
++
HER2/ErbB2, IC50: 10 nM |
98+% | |||||||||||||||||
Lapatinib |
+++
ErbB2, IC50: 9.2 nM |
EGFR | 98% | ||||||||||||||||
AEE788 |
++++
HER2/ErbB2, IC50: 6 nM |
EGFR | 98+% | ||||||||||||||||
Neratinib |
+
HER2, IC50: 59 nM |
Src,EGFR | 98% | ||||||||||||||||
BMS-599626 |
+
HER2, IC50: 30 nM |
99+% | |||||||||||||||||
Mubritinib |
++++
HER2/ErbB2, IC50: 6.0 nM |
99%+ | |||||||||||||||||
Tucatinib |
+++
ErbB2, IC50: 8 nM |
98% | |||||||||||||||||
Sapitinib |
++++
ErbB2, IC50: 3 nM |
EGFR | 99%+ | ||||||||||||||||
CUDC-101 |
++
HER2, IC50: 15.7 nM |
EGFR,HDAC | 99%+ | ||||||||||||||||
Afatinib dimaleate |
++
HER2, IC50: 14 nM |
98% | |||||||||||||||||
Afatinib |
++
HER2, IC50: 14 nM |
99% | |||||||||||||||||
Pertuzumab | ✔ | 95% | |||||||||||||||||
Trastuzumab | ✔ | 98% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | Human epidermal growth factor receptor (EGFR; HER1,erbB1), human epidermal growth factor r eceptor 2 (HER2; erbB2), HER3 (erbB3) and HER4 (erbB4) are members of the ErbB family of transmembrane receptor tyrosine kinases. Among them, HER2 is a validated and high-value target. Overexpression of HER2 occurs in gastric, colorectal, NSCLC, breast and ovarian cancers. Mubritinib is a highly selective Her2 inhibitor with IC50 value of 6nM (measured by tyrosine-kinase activity), with almost no inhibition of other related target including EGFR, FGFR, PDGFR, Jak1, Src and Blk (all IC50 values>25000nM). Treatment with mubritinib at concentration>0.1μM for 2h caused significant decrease of autophosphorylation of Her2, as well as phosphorylation level of the key signal transduction mediator AKT and MAPK, in BT474 cells overexpressing HER2. The sensitivity of cell to Mubritinib depended on HER2 levels, as BT474 cells over-expressing HER2 strongly with highly sensitivity to Mubritinib (IC50=0.005µM), PC-3 cells expressing HER2 very weakly with less sensitive to Mubritinib (IC50=4.62µM), and HT1376 and ACHN cells over-expressed EGFR with much higher IC50 values (>25μM). Oral administration of 20mg/kg Mubritinib twice daily for 2 weeks significantly inhibited tumor growth in UMUC-3 bladder cancer model, as well as LN-REC4 prostate cancer model at dose of 10 or 20mg/kg[1]. |
Dose | Mice[1] (p.o.): 10 m/kg, 20 mg/kg |
Administration | p.o. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00034281 | Breast Neoplasm ... 展开 >> Pancreatic Neoplasm Lung Neoplasm Ovarian Neoplasm Renal Neoplasm 收起 << | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Arizona Cancer Center Scottsdale, Arizona, United States, 85258 United States, Texas The Institute for Drug Development San Antonio, Texas, United States, 78229 Brooke Army Medical Center/Drug Development Unit San Antonio, Texas, United States, 78234 South Texas VA, Audie Murphy Division San Antonio, Texas, United States, 78284 收起 << |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.13mL 0.43mL 0.21mL |
10.67mL 2.13mL 1.07mL |
21.35mL 4.27mL 2.13mL |
CAS号 | 366017-09-6 |
分子式 | C25H23F3N4O2 |
分子量 | 468.471 |
别名 | TAK-165 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,2-8°C |
溶解度 |
DMSO: 50 mg/mL(106.73 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |
IP 2% DMSO+2% Tween80+40% PEG300+water 2 mg/mL clear PO 0.5% CMC-Na 18 mg/mL suspension |